mRNA Vaccines Are Here to Stay: Debunking Myths and False Information
This blog entry provides an overview of the history and future of mRNA vaccines.
This blog entry provides an overview of the history and future of mRNA vaccines.
Explore AIM’s one-pager about collaboration opportunities between immunization programs (IPs) and maternal child health (MCH) programs.
As part of the Vaccine Access Cooperative (VAC) project, this collection of jurisdiction profiles details AIM’s Beaches region.
At the Frontier and Beaches VAC meetings, Julissa Soto, an independent health equity consultant, presented on the power of cultural validation for immigrants and refugees.
On July 9, 2025, the FDA released its decision to approve the supplemental Biologics License Application (BLA) for SPIKEVAX, but only for certain ages at high risk.
Increasing adolescent vaccination coverage is essential to safeguarding public health and preventing outbreaks of vaccine-preventable diseases. This toolkit offers a selection of resources and insight into activities and strategies to…
AIM partnered with CHWs in five states to develop and implement COVID-19 household reminder postcard campaigns with messaging developed by trusted leaders.
AIM's reminder/recall (RR) program aims to increase immunization rates by assisting members in designing and coordinating reminder/recall postcard mailings.
AIM invites participation in its Immunization Program and Birthing Institution Community of Practice (CoP) to Optimize Administration of Birth Dose Immunizations.
Likely you’ve heard some back-and-forth recently about the use of aluminum as an adjuvant in vaccines. Here’s what you need to know from both sides of the argument.